NO20061324L - Polymorfe former av en kjent antihyperlinemisk forbindelse - Google Patents

Polymorfe former av en kjent antihyperlinemisk forbindelse

Info

Publication number
NO20061324L
NO20061324L NO20061324A NO20061324A NO20061324L NO 20061324 L NO20061324 L NO 20061324L NO 20061324 A NO20061324 A NO 20061324A NO 20061324 A NO20061324 A NO 20061324A NO 20061324 L NO20061324 L NO 20061324L
Authority
NO
Norway
Prior art keywords
polymorphic forms
antihyperlinemic
compound
preparation
dihydroxyheptide
Prior art date
Application number
NO20061324A
Other languages
English (en)
Inventor
Nigel Phillip Taylor
Kenneth Edwin Herbert Warren
Simon Nicholas Black
Lianne Owens
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20061324L publication Critical patent/NO20061324L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

To nye polymorfe former av (E)-7-[4-(4-fIuorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin 5-y1](3R,5S)-3,5-dihydroksyhept-6-ensyre tris(hydroksymetyl)metylammoniumsalt (1), metoder for fremstilling av disse og anvendelse av disse ved fremstilling av farmasøytisk anvendelige preparater ved behandling av, bl.a. hyperkolesterolermi, hyperlipoproteinemi og aterosklerose er beskrevet.
NO20061324A 2003-09-18 2006-03-23 Polymorfe former av en kjent antihyperlinemisk forbindelse NO20061324L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321827.8A GB0321827D0 (en) 2003-09-18 2003-09-18 Chemical compounds
PCT/GB2004/004133 WO2005028450A1 (en) 2003-09-18 2004-09-17 Polymorphic forms of a known antihyperlipemic agent

Publications (1)

Publication Number Publication Date
NO20061324L true NO20061324L (no) 2006-04-04

Family

ID=29227290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061324A NO20061324L (no) 2003-09-18 2006-03-23 Polymorfe former av en kjent antihyperlinemisk forbindelse

Country Status (13)

Country Link
US (1) US20070105882A1 (no)
EP (1) EP1663990A1 (no)
JP (1) JP2007505879A (no)
CN (1) CN100439342C (no)
AU (1) AU2004274239B2 (no)
BR (1) BRPI0414499A (no)
CA (1) CA2538756A1 (no)
GB (1) GB0321827D0 (no)
IL (1) IL174164A0 (no)
NO (1) NO20061324L (no)
NZ (1) NZ546007A (no)
WO (1) WO2005028450A1 (no)
ZA (1) ZA200602263B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
HUP0401248A3 (en) 2001-07-13 2004-11-29 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds and new intermediates
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
JP4579821B2 (ja) 2002-12-16 2010-11-10 アストラゼネカ・ユーケイ・リミテッド ピリミジン化合物を製造するための方法
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2010082072A1 (en) * 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL158525A0 (en) * 2001-06-06 2004-05-12 Bristol Myers Squibb Co A process for preparing chiral diol sulfone derivatives
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium

Also Published As

Publication number Publication date
CN100439342C (zh) 2008-12-03
EP1663990A1 (en) 2006-06-07
WO2005028450A1 (en) 2005-03-31
AU2004274239A1 (en) 2005-03-31
AU2004274239B2 (en) 2008-12-04
IL174164A0 (en) 2006-08-01
CA2538756A1 (en) 2005-03-31
NZ546007A (en) 2008-11-28
US20070105882A1 (en) 2007-05-10
BRPI0414499A (pt) 2006-11-14
ZA200602263B (en) 2007-11-28
CN1852899A (zh) 2006-10-25
JP2007505879A (ja) 2007-03-15
GB0321827D0 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
NO20061324L (no) Polymorfe former av en kjent antihyperlinemisk forbindelse
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
CY1109173T1 (el) Κρυσταλλικη μορφη του δις [(ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3r,5s)-3,5-διϋδροξυεπτ-6-ενοϊκο οξυ] αλατος ασβεστιου
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
DK1144389T3 (da) Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
RS50201B (sr) FARMACEUTSKE KOMPOZICIJE KOJE OBUHVATAJU INHIBITOR HMG CoA REDUKTAZE
MY135301A (en) Chemical process
CA2429263A1 (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
AR043594A1 (es) Un procedimiento para la preparacion de la sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfonil)amino]pirimidin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y compuesto utilizable en dicho procedimiento

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application